Markets:

Overview

News

Currencies

International

Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

70.33 -2.28 (-3.15%)

Delayed Quote Updated: 12:30 PM EST, Nov 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 Next >

CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup ↗

August 19, 2026

Via Chartmill

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead ↗

June 10, 2026

CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global...

Via MarketBeat

Topics Initial Public Offering

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push ↗

June 07, 2026

CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the...

Via MarketBeat

Topics Initial Public Offering

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference ↗

May 20, 2026

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder...

Via MarketBeat

Topics Initial Public Offering

CG Oncology Inc (NASDAQ:CGON) Shows Perfect Technical Rating and Strong Setup Quality for Potential Breakout ↗

May 11, 2026

Via Chartmill

CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears ↗

May 15, 2026

CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder...

Via MarketBeat

Topics Initial Public Offering

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings ↗

May 11, 2026

CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets.

Via Benzinga

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Via The Motley Fool

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Via The Motley Fool

Topics Regulatory Compliance

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise...

Via MarketMinute

Topics Earnings Economy

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

Via The Motley Fool

Topics Regulatory Compliance

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

Via MarketMinute

Topics Intellectual Property

What's going on in today's session ↗

January 09, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Friday's session. ↗

January 09, 2026

Via Chartmill

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

A full exit during a volatile stretch raises a sharper question than timing alone.

Via The Motley Fool

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

Why Cg Oncology Stock Rocketed 7% Higher Today ↗

October 08, 2025

One pundit believes this is a clinical-stage company well worth watching.

Via The Motley Fool

CG Oncology Stock Signals Bullish Momentum Ahead ↗

September 08, 2025

CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track...

Via Benzinga

Cg Oncology (CGON) Q2 Loss Widens 93% ↗

August 08, 2025

Via The Motley Fool

Which stocks are moving before the opening bell on Tuesday? ↗

July 22, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 22, 2025

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock ↗

July 16, 2025

Via Benzinga

Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗

May 04, 2025

Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?

Via Benzinga

Topics Artificial Intelligence

These stocks are moving in today's session ↗

April 28, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

CG Oncology, Inc. - Common stock (NQ:CGON)

Headline News about CG Oncology, Inc. - Common stock

Starting at /week.